Get the Stockscreener App
711.68
0.26%
1.86
After Hours:
710.15
-1.53
-0.21%
Overview
News
Price History
Option Chain
Financials
Why LLY Down?
Discussions
Forecast
Stock Split
Dividend History
Lilly Eli Co stock is traded at $711.68, with a volume of 3.19M.
It is up +0.26% in the last 24 hours and down -8.34% over the past month.
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
See More
Previous Close:
$709.82
Open:
$715.04
24h Volume:
3.19M
Relative Volume:
0.74
Market Cap:
$673.57B
Revenue:
$53.26B
Net Income/Loss:
$13.80B
P/E Ratio:
46.52
EPS:
15.3
Net Cash Flow:
$-50.20M
1W Performance:
+1.49%
1M Performance:
-8.34%
6M Performance:
-18.54%
1Y Performance:
-25.41%
1-Day Range:
$709.43
$719.46
1-Week Range:
$685.15
$719.46
52-Week Range:
$623.78
$972.48
Lilly Eli Co Stock (LLY) Company Profile
Name
Lilly Eli Co
Sector
Industry
Phone
(317) 276-2000
Address
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Compare LLY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
711.68 | 625.77B | 53.26B | 13.80B | -50.20M | 15.30 |
|
JNJ
Johnson Johnson
|
179.29 | 424.47B | 90.62B | 22.66B | 18.18B | 9.35 |
|
ABBV
Abbvie Inc
|
210.60 | 364.92B | 58.33B | 3.73B | 18.24B | 2.10 |
|
NVS
Novartis Ag Adr
|
126.98 | 240.07B | 53.40B | 13.68B | 16.89B | 6.9231 |
|
MRK
Merck Co Inc
|
87.37 | 210.36B | 63.43B | 16.42B | 14.72B | 6.49 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-18-25 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Aug-07-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jun-05-25 | Downgrade | Erste Group | Buy → Hold |
| Apr-28-25 | Downgrade | HSBC Securities | Buy → Reduce |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Sep-13-24 | Resumed | Citigroup | Buy |
| Aug-12-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-21-24 | Downgrade | DZ Bank | Buy → Hold |
| Feb-16-24 | Reiterated | Morgan Stanley | Overweight |
| Dec-21-23 | Downgrade | Daiwa Securities | Buy → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-20-23 | Resumed | UBS | Buy |
| Aug-09-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-26-23 | Reiterated | Citigroup | Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| May-24-23 | Reiterated | BofA Securities | Buy |
| May-24-23 | Reiterated | UBS | Buy |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Feb-15-23 | Downgrade | Societe Generale | Hold → Sell |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Sep-22-22 | Upgrade | UBS | Neutral → Buy |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Mar-10-22 | Initiated | Daiwa Securities | Outperform |
| Jan-21-22 | Upgrade | DZ Bank | Hold → Buy |
| Jan-03-22 | Reiterated | Bernstein | Mkt Perform |
| Dec-17-21 | Initiated | Goldman | Neutral |
| Dec-16-21 | Reiterated | BMO Capital Markets | Outperform |
| Dec-16-21 | Reiterated | BofA Securities | Buy |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Oct-11-21 | Upgrade | Berenberg | Hold → Buy |
| Sep-29-21 | Upgrade | Citigroup | Neutral → Buy |
| Aug-05-21 | Upgrade | DZ Bank | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Jun-24-21 | Reiterated | Cantor Fitzgerald | Overweight |
| Jan-19-21 | Upgrade | Mizuho | Neutral → Buy |
| Dec-10-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Sep-03-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-16-20 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-21-20 | Downgrade | UBS | Buy → Neutral |
| Apr-09-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Dec-18-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| May-28-19 | Initiated | Goldman | Buy |
| Apr-24-19 | Upgrade | Edward Jones | Hold → Buy |
| Apr-11-19 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-12-19 | Initiated | JP Morgan | Overweight |
| Jan-23-19 | Initiated | UBS | Buy |
| Nov-26-18 | Downgrade | Citigroup | Buy → Neutral |
| Oct-31-18 | Upgrade | Credit Suisse | Underperform → Neutral |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Oct-01-18 | Reiterated | SunTrust | Buy |
| Sep-26-18 | Resumed | JP Morgan | Overweight |
View All
Lilly Eli Co Stock (LLY) Latest News
Eli Lilly & Co Completes $6.71 Billion Notes Issuance - TipRanks
Eli Lilly Neuroscience Head Anne White to Retire After Three Decades with Company - geneonline.com
Lilly searching for new neuro chief as White set to retire - BioPharma Dive
Novo Nordisk Freezes Hiring As Wegovy Faces Copycats - Benzinga
What's Going on With Eli Lilly Stock? - The Motley Fool
30-Year Veteran Who Led Lilly's Historic Alzheimer's Drug Launch: Anne White Announces Retirement - Stock Titan
Stock Option Traders Smell Blood in the Water After Eli Lilly’s (LLY) Q2 Fumble - TipRanks
New Obesity Drugs May See Premium Pricing Undermined By Underwhelming Data - Benzinga
Eli Lilly (LLY) Sells Record $6.75 Billion of Corporate Bonds - TipRanks
How does Viking’s oral obesity drug stand up to those of Eli Lilly and Novo? - Seeking Alpha
Mixed options sentiment in Eli Lilly with shares up 1.67% - TipRanks
Eli Lilly & Co’s Orforglipron Faces Hold Rating Amid Concerns Over GI Side Effects in Clinical Trials - TipRanks
Positive Market Outlook for Eli Lilly’s Orforglipron Following ATTAIN-1 Trial Results - TipRanks
Like Eli Lilly, Viking Therapeutics' Oral Weight Loss Drug Disappoints, Stock Tanks - Benzinga
Eli Lilly Considering Viking Therapeutics Acquisition?… - inkl
Eli Lilly Considering Viking Therapeutics Acquisition? Expert Says 'They're Setting Up For Something BIG' As LLY Issues 40-Year BondInvesco QQQ Trust, Series 1 (NASDAQ:QQQ), Eli Lilly (NYSE:LLY) - Benzinga
Eli Lilly (NYSE:LLY): This US$700bn company is set to beat Novo Nordisk & Ozempic even with this month's hiccup - Stocks Down Under
Analysts Rally Behind Eli Lilly (LLY) Stock After 24% Slide - TipRanks
Eli Lilly Files for $6.75 Billion Bond Offering - AInvest
Eli Lilly files for six-part notes offering of up to $6.75 billion - MarketScreener
Eli Lilly Taps High-Grade Bond Market With Rare 40-Year Paper - Bloomberg.com
Eli Lilly Launches $6.75 Billion Debt Offering - MarketScreener
Wall Street sees new obesity pills as priced near Wegovy and Zepbound - Reuters
Eli Lilly and Company Stock (LLY) Opinions on Orforglipron Trial Data - Quiver Quantitative
Eli Lilly Taps High-Grade Market With Rare 40-Year Paper - Yahoo Finance
Lilly Stock Down 5% This Month: Should You Buy the Dip? - uk.finance.yahoo.com
Superluminal joins a $1.3B deal with series A backer Lilly - BioWorld MedTech
Form 424B2 ELI LILLY & Co - StreetInsider
Daiwa Securities Downgrades Eli Lilly to Neutral From Outperform, Cuts Price Target to $700 From $940 - MarketScreener
The stock price pullback creates a good buying opportunity, and Eli Lilly and Co may soon join the "trillion-dollar club." - 富途牛牛
Superluminal Medicines, Eli Lilly forge USD 1.3 billion alliance to advance Small Molecule Therapeutics - Medical Dialogues
Eli Lilly and Company (LLY) Announces Results From LTE of Phase 3 TRAILBLAZER-ALZ 2 Study - uk.finance.yahoo.com
Eli Lilly: A Biotech Powerhouse Rewriting the Rules of Long-Term Growth - AInvest
Eli Lilly: Don't Bet Against This Biotech Powerhouse (NYSE:LLY) - Seeking Alpha
Eli Lilly's Q2 2025 Outperformance and Orforglipron Pipeline: A New Era for Obesity and Diabetes Therapies - AInvest
Eli Lilly (LLY) Raises Mounjaro Prices in UK, Stock Reacts Positively - MSN
Eli Lilly and Company (LLY) Releases Q2 2025 Results - uk.finance.yahoo.com
Eli Lilly’s Stock Soars Amid Promising Trials - TipRanks
Is Eli Lilly Stock a Buy? Here's What the Market Isn't Pricing in Yet. - AOL.com
Novo Nordisk vs. Eli Lilly: Is the GLP-1 Correction Over, and Who's Better Positioned for Long-Term Leadership? - AInvest
Insider Moves: Microsoft, AMD, Boeing, AbbVie, Eli Lilly - TipRanks
Did Eli Lilly Stock Just Have Its Novo Nordisk Moment? - MSN
Eli Lilly Insider Buying: Lucas Montarce Purchases 715 Shares - AInvest
LLY CFO Makes Significant Investment in Eli Lilly & Co Stock - AInvest
Eli Lilly to sell troubled N.J. pharmaceutical plant, but says jobs are safe. Here’s why. - MSN
Eli Lilly & Co’s CFO Makes a Bold Move with New Stock Purchase! - TipRanks
Eli Lilly and Co Options Spot-On: On August 15th, 243.55K Contracts Were Traded, With 573.94K Open Interest - 富途牛牛
Eli Lilly & Co. hikes UK weight-loss drug’s price amid pressure from Trump - WISH-TV
Eli Lilly: Bet Against Insiders (NYSE:LLY) - Seeking Alpha
Eli Lilly (LLY) CEO Buys $1 Million of Company Stock After Recent Crash - MSN
Eli Lilly and health-care stocks are week's big winners, 3 sectors in the red - CNBC
Lilly Eli Co Stock (LLY) Financials Data
Revenue
Net Income
Cash Flow
EPS
Lilly Eli Co Stock (LLY) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Alvarez Ralph | Director |
Aug 13 '25 |
Buy |
660.25 |
758 |
500,473 |
758 |
| Van Naarden Jacob | EVP & Pres., Lilly Oncology |
Aug 13 '25 |
Buy |
647.36 |
1,000 |
647,360 |
20,562 |
| Ricks David A | President, Chair, and CEO |
Aug 12 '25 |
Buy |
644.77 |
1,632 |
1,052,263 |
546,601 |
| Skovronsky Daniel | EVP, CSO & Pres. LRL & LLY Imm |
Aug 12 '25 |
Buy |
634.40 |
1,000 |
634,405 |
137,660 |
| Sulzberger Gabrielle | Director |
Aug 12 '25 |
Buy |
641.18 |
117 |
75,018 |
2,703 |
| Fyrwald J Erik | Director |
Aug 12 '25 |
Buy |
642.33 |
1,565 |
1,005,242 |
74,578 |
| Yuffa Ilya | EVP&Pres, LLY USA&Global Capab |
Aug 11 '25 |
Sale |
627.01 |
1,250 |
783,762 |
26,260 |
| JACKSON JAMERE | Director |
Aug 08 '25 |
Buy |
639.56 |
200 |
127,913 |
9,402 |
| Seymour Melissa | EVP, Global Quality |
Aug 01 '25 |
Option Exercise |
0.00 |
952 |
0 |
952 |
| LILLY ENDOWMENT INC | 10% Owner |
Jul 24 '25 |
Sale |
805.07 |
280,000 |
225,419,259 |
95,736,978 |
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):